期刊文献+

Inflammation and vascular disease: the role of C-reactive protein

Inflammation and vascular disease: the role of C-reactive protein
在线阅读 下载PDF
导出
摘要 Inflammation is an important component of active atherosclerotic disease. C-reactive protein (CRP)is a non-specific inflammatory marker that is increased in inflammatory conditions. Newer more sensitive assays (high sensitivity CRP) can detect the low levels of inflammation associated with vascular disease. CRP levels can give further risk assessment to individuals beyond predictions from traditional risk factors. This measurement is most useful in helping to discriminate risk in intermediate risk patients such as metabolic syndrome patients. Exercise and weight loss have been shown to significantly lower CRP levels. Lipid lowering therapies, especially with the statin class of medications, also lower CRP levels. A reduction in inflammation may be an important component of plaque stabilization and contribute to cardiovascular risk reduction. Inflammation is an important component of active atherosclerotic disease.C-reactive protein (CRP) is a non-specific inflammatory marker that is increased in inflammatory conditions.Newer more sensitive assays (high sensitivity CRP) can detect the low levels of inflammation associated with vascular disease.CRP levels can give further risk assessment to individuals beyond predictions from traditional risk factors.This measurement is most useful in helping to discriminate risk in intermediate risk patients such as metabolic syndrome patients.Exercise and weight loss have been shown to significantly lower CRP levels.Lipid lowering therapies,especially with the statin class of medications,also lower CRP levels.A reduction in inflammation may be an important component of plaque stabilization and contribute to cardiovascular risk reduction.(J Geriatr Cardiol 2004;1:17-20.)
出处 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2004年第1期17-20,共4页 老年心脏病学杂志(英文版)
  • 相关文献

参考文献10

  • 1Sesso HD,Buring JE,Rifai N,et al.C-reactive protein and the risk of developing hypertension[].The Journal of The American Medical Association.2003
  • 2Ridker PM,Buring JE,Cook NR,et al.C-Reactive protein, the metabolic syndrome,and risk of incident cardiovascular events[].Circulation.2003
  • 3McLaughlin T,Abbessi F,Lamerdola C,at al.Differentiation between obesity and insulin resistance in the association with Creactive protein[].Circulation.2002
  • 4Albert MA,Danielson E,Rifai N,et al.Effect of statin therapy on C-Reactive protein levels.The Pravastatin Inflammation/CRP evaluation (PRINCE):A randomized trial and cohort study[].The Journal of The American Medical Association.2001
  • 5Nissen SE,Tuzeu EM,Schoenhagen P,et al.Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis[].The Journal of The American Medical Association.2004
  • 6Pradham AD,Manson JE,Rifai N,et al.C-reactive protein, interleukin 6,and risk of developing type 2 diabetes mellitus[].The Journal of The American Medical Association.2001
  • 7Koenig W,Lowel H,Baumert J,et al.C-reactive protein modulates risk prediction based on the Framingham score.Implications for future risk assessment:Results from a large cohort study in Southern Germany[].Circulation.2004
  • 8Pearson TA,Mensah GA,Alexander RW,et al.Markers of inflammation and cardiovascular disease[].Circulation.2003
  • 9Ridker PM,Cook N.Clinical usefulness of very high and very low levels of C-reactive protein across a full range of Framingham risk scores[].Circulation.2004
  • 10Visser M,Bouter LM,McQuillan GM,et al.Elevated Creactive protein levels in overweight and obese adults[].The Journal of The American Medical Association.1999

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部